Drug Profile
Empesertib - Bayer
Alternative Names: BAY-1161909Latest Information Update: 17 Dec 2018
Price :
$50
*
At a glance
- Originator Bayer
- Class Antineoplastics; Pyridines
- Mechanism of Action TTK protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 13 Nov 2018 Pharmacodynamics data from a preclinical study in Solid tumour presented at the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2018)
- 19 Oct 2018 Efficacy and adverse events data from a phase I trial in Solid tumours presented at the 43rd European Society for Medical Oncology Congress (ESMO-2018)
- 28 Apr 2018 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (PO)